Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 10,535 matching trials from the live ClinicalTrials.gov search.

Filters: Active, not recruiting Clear all

Conditions: Androgen Receptor Positive, Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Salivary Duct Carcinoma, Salivary Gland Adenocarcinoma, NOS, Salivary Gland Basal Cell Adenocarcinoma, Stage III Major Salivary Gland Cancer AJCC v7
Interventions: enzalutamide; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 287
States / cities: Anchorage, Alaska • Anaheim, California • Baldwin Park, California + 201 more

Conditions: Liver Cancer
Interventions: TriSalus™ TriNav™Infusion System, Angiogram, Y90-radioembolization procedure; Device · Diagnostic Test · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Fluid Overload, POCUS, Lung Ultrasound, Volume Status
Interventions: point-of-care ultrasound (POCUS), specifically lung ultrasound (LUS), Modified Medical Research Council (mMRC) Dyspnea scale, Physical Exam; Device · Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Renal Cell Carcinoma, Melanoma, Non Small Cell Lung Cancer, Gastric Cancer, Colorectal Cancer
Interventions: HFB200603, Tislelizumab; Drug
Lead sponsor: HiFiBiO Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Los Angeles, California • Philadelphia, Pennsylvania • Fairfax, Virginia

Conditions: Weight Stigma
Interventions: Health at Every Size in Obstetrics; Behavioral
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Recurrent Lung Small Cell Carcinoma
Interventions: Laboratory Biomarker Analysis, Placebo Administration, Temozolomide, Veliparib; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2027
U.S. locations: 14
States / cities: Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 10 more

Conditions: Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
Interventions: LY3410738, Gemcitabine, Cisplatin, Durvalumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 17
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 13 more

Conditions: Breast Cancer
Interventions: Proton Beam Radiotherapy; Radiation
Lead sponsor: Loma Linda University; Other
Eligibility: 40 Years to 80 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2026
U.S. locations: 2
States / cities: Loma Linda, California

Conditions: Pelvic Floor Disorder, Loneliness, Postpartum, Mental Health, Depression, Peritraumatic Distress, Women, Artificial Intelligence (AI), Chatbot
Interventions: Generative artificial intelligence (genAI) postpartum chatbot, Standard of Care (SOC); Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Female only
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Lewy Body Dementia, Parkinson Disease Dementia, Dementia With Lewy Bodies, Lewy Body Disease
Interventions: Peer Mentor Support and Caregiver Education, Caregiver Education; Behavioral
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 622 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Recurrent Distal Bile Duct Adenocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Intrahepatic Cholangiocarcinoma, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Liver Carcinoma
Interventions: Atezolizumab, Biopsy, Biospecimen Collection, Cobimetinib, Computed Tomography, Magnetic Resonance Imaging, Varlilumab; Biological · Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 29
States / cities: Phoenix, Arizona • Duarte, California • Los Angeles, California + 22 more

Conditions: Glioblastoma
Interventions: Accelerated Hypofractionated Radiation Therapy, Computed Tomography, Fluorodopa F 18, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Temozolomide, Biospecimen Collection; Radiation · Procedure · Drug + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 8
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 5 more

Conditions: Metabolic Syndrome, Breast Cancer Prevention, Physical Activity
Interventions: Enhanced physical activity monitor which is Fitbit watch with mobile App, Bollywood-style group dance, PAMDance; Behavioral
Lead sponsor: Rush University Medical Center; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Chicago, Illinois • Sugar Grove, Illinois

Conditions: Psoriasis
Interventions: transcutaneous electrical nerve stimulation (TENS) unit; Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 64 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Advanced Malignant Solid Neoplasm, Advanced Peritoneal Malignant Mesothelioma, Advanced Pleural Malignant Mesothelioma, Recurrent Peritoneal Malignant Mesothelioma, Recurrent Pleural Malignant Mesothelioma, Refractory Malignant Solid Neoplasm, Unresectable Solid Neoplasm
Interventions: Cisplatin, Methoxyamine, Pemetrexed Disodium; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 14
States / cities: Duarte, California • Los Angeles, California • Pasadena, California + 9 more

Conditions: Muscle Performance, Sarcopenic Obesity
Interventions: IMM01-STEM, Placebo, IMM01-STEM alternating with placebo (saline); Biological · Other
Lead sponsor: Immunis, Inc.; Industry
Eligibility: 60 Years to 80 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 4
States / cities: Garden Grove, California • Pomona, California • Lenexa, Kansas + 1 more

Conditions: Obesity, Overeating, Food Addiction
Interventions: Intake of nutritionally diverse ultra-processed foods; Other
Lead sponsor: Oregon Research Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Locally Recurrent/Metastatic Triple Negative Breast Cancer
Interventions: external beam radiation therapy, cisplatin, Biopsy of Target Tumor; Radiation · Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent pneumococcal conjugate vaccine (13-PCV), 23-valent pneumococcal polysaccharide vaccine (23-PPV), Seasonal Quadrivalent influenza vaccine, Keyhole limpet hemocyanin (KLH) neo-antigen; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 1,882 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 86
States / cities: Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 74 more

Conditions: Mindfulness, Psychophysiologic Reaction, Behavior, Health
Interventions: Online Mindfulness Based Stress Reduction; Behavioral
Lead sponsor: San Jose State University; Other
Eligibility: 21 Years to 64 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: San Jose, California

Conditions: Glioblastoma
Interventions: IDO1 Inhibitor BMS-986205 25mg, Nivolumab, Radiation Therapy, Temozolomide, IDO1 Inhibitor BMS-986205 50 mg, IDO1 Inhibitor BMS-986205 100 mg; Drug · Radiation
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Thyroid Eye Disease
Interventions: AMG 732, Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 12
States / cities: Little Rock, Arkansas • Newport Beach, California • Jacksonville, Florida + 9 more

Conditions: Dry Needling Technique, Neck Pain Musculoskeletal, Shoulder Pain, Neck Pain, Dry Needling
Interventions: Dry Needling; Other
Lead sponsor: Texas Woman's University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD), EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma
Interventions: Tabelecleucel; Biological
Lead sponsor: Pierre Fabre Medicament; Industry
Eligibility: Not listed
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 23
States / cities: Los Angeles, California • Orange, California • Palo Alto, California + 18 more

Search by objective public record fields.

Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers

TriNav Infusion System for the Evaluation of Fidelity Between 99mTc-MAA and Y90-Microspheres Hepatic Distribution for Dosimetry Treatment Planning

Concordance and Discordance in the Assessment of Volume Status in Home Dialysis Patients: A Comparison of Modified Medical Research Council Dyspnea Scale, Physical Exam, and Point of Care Ultrasound (POCUS)

A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

Adapting a Health at Every Size Intervention to Obstetric Care

Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Partial Breast Proton Therapy for Early Stage Breast Cancer

Postpartum Education Via Artificial Intelligence for Recovery and Loneliness: A Randomized Controlled Trial

PERSEVERE: Peer Mentor Support and Caregiver Education in Lewy Body Dementia

Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer

Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study

Physical Activity Targeting Metabolic Syndrome for Prevention of Breast Cancer in SAI Women

Use of Transcutaneous Electrical Nerve Stimulation for Reducing Biologic Injection Site Pain(TENS Study)

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

Safety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Seniors With Obesity and Muscle Weakness

Biobehavioral Reward Responses Associated With Consumption of Nutritionally Diverse Ultra-Processed Foods

Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

Online Mindfulness-based Program for Parents of Children With Autism

Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

How Dry Needling at the Neck Affects Shoulder Movement, Strength, Pain, and Shoulder Circulation

A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases